The Latest

This Week in HIV Research: The Racism of Perceived Risk

June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.

By Barbara Jungwirth and Myles Helfand

Ending the HIV Epidemic Will Take More Than Medicine

Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

By Stephaun E. Wallace, Ph.D.

Making Trans Women Count in HIV Vaccine Trials

"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.

By Stephen Hicks

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

Results of CDC-Funded Local Projects for MSM and Transgender People Unveiled at Prevention Conference

Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.

By Sony Salzman

Mixed Findings on HIV Prevalence Trends Among U.S. Trans Women

A new systematic review conducted by researchers at the CDC estimates that 14% of trans women and 3% of trans men are living with HIV. The estimate in trans women is lower than previous calculations, but still shows that trans people are a vulnerable population with a substantial risk of contracting HIV.

By Martha Kempner

New Study Triggers Concerns Over Use of Molecular HIV Surveillance

This study identified some information about transgender women's sexual networks in Los Angeles. But activists worry about privacy and the potential that the surveillance method will be used in HIV criminalization cases.

By Martha Kempner

HIV Prevalence Among Transgender Women Lower Than Previously Estimated, but Rates May Not Be Going Down, New CDC Study Finds

New data from CDC show that rates of HIV infection among transgender women in the U.S. are lower than previous estimates, but still, nearly 45% of black transgender women are living with HIV.

By Martha Kempner

This Week in HIV Research: Transgender Women in the Spotlight

Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?

By Barbara Jungwirth and Myles Helfand

For Transgender Women, PrEP Is Safe to Use With Estradiol as Feminizing Hormone Therapy, Study Says

The findings mark a crucial point in the history of PrEP delivery among trans women, as they offer clarity for health care providers, PrEP outreach campaigns, and trans women using estradiol as feminizing hormone therapy.

By Arjee Javellana Restar